UL
MCID: LMY014
MIFTS: 56

Leiomyoma, Uterine (UL)

Categories: Cancer diseases, Muscle diseases, Nephrological diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leiomyoma, Uterine

MalaCards integrated aliases for Leiomyoma, Uterine:

Name: Leiomyoma, Uterine 57
Uterine Leiomyoma 11 28 53 5
Uterine Fibroids 41 14 63 71
Uterine Fibroid 11 14 16 75
Plexiform Leiomyoma 11 71
Leiomyoma of Corpus Uteri 11
Uterus Fibroma 11
Ul 57

Characteristics:


Inheritance:

Somatic mutation 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
uterine leiomyomata are found in hereditary leiomyomatosis and renal cell cancer syndrome


Classifications:



External Ids:

Disease Ontology 11 DOID:13223
OMIM® 57 150699
ICD9CM 34 218
MeSH 43 D007889
NCIt 49 C3434
SNOMED-CT 68 44598004
ICD10 31 D25
MedGen 40 C0042133
SNOMED-CT via HPO 69 146801000119103 95315005
UMLS 71 C0042133 C2242776

Summaries for Leiomyoma, Uterine

MedlinePlus: 41 Uterine fibroids are the most common benign tumors in women of childbearing age. Fibroids are made of muscle cells and other tissues that grow in and around the wall of the uterus, or womb. The cause of fibroids is unknown. Risk factors include being African American or being overweight. Many women with fibroids have no symptoms. If you do have symptoms, they may include: Heavy or painful periods or bleeding between periods Feeling "full" in the lower abdomen Urinating often Pain during sex Lower back pain Reproductive problems, such as infertility, multiple miscarriages or early labor Your health care provider may find fibroids during a gynecological exam or by using imaging tests. Treatment includes drugs that can slow or stop their growth, or surgery. If you have no symptoms, you may not even need treatment. Many women with fibroids can get pregnant naturally. For those who cannot, infertility treatments may help. NIH: National Institute of Child Health and Human Development

MalaCards based summary: Leiomyoma, Uterine, also known as uterine leiomyoma, is related to kidney cancer and cystic echinococcosis, and has symptoms including pelvic pain An important gene associated with Leiomyoma, Uterine is MIRLET7C (MicroRNA Let-7c), and among its related pathways/superpathways are Interactions between immune cells and microRNAs in tumor microenvironment and miRNAs involved in DNA damage response. The drugs Progesterone and Cetrorelix have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotype is uterine leiomyoma.

PubMed Health : 63 Uterine fibroids: Many women have benign (non-cancerous) growths known as fibroids in or on their womb (uterus). Most fibroids are small and don't cause any problems. They are usually discovered by chance. Depending on where fibroids are located, they may cause period pain, heavy menstrual bleeding or other symptoms. There are different ways to treat fibroids. The most suitable treatment will greatly depend on a woman’s individual circumstances – such as whether she would still like to have children. Fibroids are made up of muscle cells and connective tissue. Their size, shape and location vary. Fibroids are mainly categorized based on where they are:

OMIM®: 57 Uterine leiomyoma (UL), commonly known as fibroids, are benign tumors of the uterine myometrium. They represent the most prevalent pelvic tumors in women and are found in more than 75% of women of reproductive age. Approximately 20 to 25% of women with UL exhibit symptoms including menorrhagia, infertility, pelvic pain, and a range of complications during pregnancy. UL are the leading cause for hysterectomy in the United States, accounting for 30% of all hysterectomies (summary by Eggert et al., 2012). (150699) (Updated 08-Dec-2022)

Disease Ontology: 11 An uterine benign neoplasm derived from the smooth muscle layer of the uterus.

Wikipedia: 75 Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the... more...

Related Diseases for Leiomyoma, Uterine

Diseases related to Leiomyoma, Uterine via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 562)
# Related Disease Score Top Affiliating Genes
1 kidney cancer 30.6 MIR30A MIR29C MIR27A MIR23B MIR21 MIR150
2 cystic echinococcosis 30.3 MIR542 MIR30A MIR21
3 cardiovascular system disease 30.3 MIR34A MIR335 MIR30A MIR27A MIR21 MIR150
4 diffuse large b-cell lymphoma 30.3 MIR21 MIR150 MIR139 MIR10A
5 rectum cancer 30.2 MIR30A MIR21 MIR150 MIR144 MIR139
6 breast disease 30.0 MIR34A MIR335 MIR30A MIR29C MIR27A MIR23B
7 ovarian disease 30.0 MIR34A MIR335 MIR30A MIR27A MIR21 MIR150
8 cerebrovascular disease 30.0 MIR335 MIR30A MIR27A MIR212 MIR21 MIR150
9 cervical cancer 30.0 MIRLET7C MIR34A MIR30A MIR27A MIR23B MIR21
10 melanoma 29.9 MIR34A MIR323A MIR27A MIR23B MIR21 MIR144
11 body mass index quantitative trait locus 11 29.9 MIR34A MIR335 MIR30A MIR27A MIR23B MIR212
12 myocardial infarction 29.9 MIR34A MIR32 MIR30A MIR212 MIR21 MIR150
13 esophageal cancer 29.8 MIR34A MIR30A MIR27A MIR23B MIR21 MIR203A
14 uterine anomalies 29.8 MIR34A MIR335 MIR30A MIR29C MIR27A MIR23B
15 lymphoma, non-hodgkin, familial 29.8 MIR34A MIR335 MIR30A MIR27A MIR23B MIR21
16 hypertension, essential 29.8 MIR34A MIR30A MIR27A MIR23B MIR212 MIR21
17 pancreatic cancer 29.6 MIR34A MIR32 MIR30A MIR23B MIR212 MIR21
18 type 2 diabetes mellitus 29.5 MIR34A MIR335 MIR30A MIR29C MIR27A MIR23B
19 renal cell carcinoma, nonpapillary 29.5 MIR34A MIR335 MIR30A MIR29C MIR27A MIR23B
20 leukemia, acute myeloid 29.4 MIRLET7C MIR542 MIR34A MIR335 MIR30A MIR27A
21 lung cancer 28.9 MIRLET7C MIR542 MIR34A MIR335 MIR32 MIR30A
22 submucous uterine fibroid 11.6
23 subserous uterine fibroid 11.6
24 myofibroma 11.2
25 benign metastasizing leiomyoma 11.2
26 uterine corpus epithelioid leiomyoma 11.1
27 uterine corpus dissecting leiomyoma 11.1
28 uterus interstitial leiomyoma 11.1
29 uterine corpus myxoid leiomyoma 11.1
30 uterine corpus lipoleiomyoma 11.1
31 uterine corpus myxoid leiomyosarcoma 11.1
32 myoma 10.7
33 leiomyomatosis 10.6
34 adenomyosis 10.5
35 amenorrhea 10.5
36 premature menopause 10.4
37 intravenous leiomyomatosis 10.4
38 granulomatous mastitis 10.4 MIRLET7C MIR21
39 vaginal discharge 10.4
40 infertility 10.4
41 lipomatosis, multiple 10.3
42 ovarian serous carcinoma 10.3 MIR27A MIR23B MIR21
43 preterm premature rupture of the membranes 10.3
44 pre-eclampsia 10.3
45 hereditary leiomyomatosis and renal cell cancer 10.3
46 rickets 10.3
47 inclusion body myositis 10.3 MIR34A MIR21 MIR197
48 pleural cancer 10.3 MIR32 MIR29C MIR21 MIR139
49 non-alcoholic steatohepatitis 10.3 MIR34A MIR21 MIR150
50 pre-malignant neoplasm 10.3 MIR30A MIR29C MIR139

Graphical network of the top 20 diseases related to Leiomyoma, Uterine:



Diseases related to Leiomyoma, Uterine

Symptoms & Phenotypes for Leiomyoma, Uterine

Human phenotypes related to Leiomyoma, Uterine:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 uterine leiomyoma 30 HP:0000131

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Genitourinary Internal Genitalia Female:
uterine leiomyomas, benign

Clinical features from OMIM®:

150699 (Updated 08-Dec-2022)

UMLS symptoms related to Leiomyoma, Uterine:


pelvic pain

Drugs & Therapeutics for Leiomyoma, Uterine

PubMed Health treatment related to Leiomyoma, Uterine: 63

Fibroids usually only need to be treated if they are causing fertility problems or could cause problems during pregnancy . The choice of treatment will mainly depend on whether a woman would still like to have children – and how she sees the advantages and disadvantages of the various treatments . The severity of the symptoms and the size and position of the fibroids may also determine which treatments are an option. There is no rush to make a treatment decision. Fibroids usually grow very slowly. So you can take your time to read up on all of the pros and cons of the different treatments . Sometimes it is also a good idea to get several opinions from different doctors. The treatment goals may include the following: Reduce menstrual bleeding Relieve pain, cramps and tension Help with difficulties emptying the bladder and digestion Preserve or improve fertility The treatment options include: Hormone therapies : The main hormone therapies are hormonal contraceptives to reduce heavy menstrual bleeding , and hormones that prevent the production of estrogens (GnRH analogues). Surgical removal of the fibroid or the entire womb . Closing off the blood vessels that supply the fibroid with blood (uterine fibroid embolization). The aim is to shrink the fibroids . Other procedures like focused ultrasound surgery (FUS) . This is a relatively new procedure, and its advantages and disadvantages have not yet been fully studied. FUS uses high-intensity ultrasound waves to heat and destroy the fibroid . Other treatments like painkillers, herbal remedies or acupuncture . NSAID (non-steroidal anti-inflammatory drug) painkillers like ibuprofen or diclofenac have been proven to relieve period pain . But there are no studies that have specifically looked into the effects of NSAIDs in women with fibroids . This is also true for acupuncture . Some herbal remedies have been studied more than others, but there's currently no evidence that they are effective in treating fibroids.

Drugs for Leiomyoma, Uterine (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887
3
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
6
Calcium carbonate Approved, Investigational Phase 4 471-34-1
7
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
8
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
9
Mecobalamin Approved, Investigational Phase 4 13422-55-4
10
Zinc oxide Approved Phase 4 1314-13-2
11
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
12
Tocopherol Approved, Investigational Phase 4 1406-66-2
13
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109
14
Plasminogen Approved Phase 4 9001-91-6
15
Ethanol Approved Phase 4 64-17-5 702
16
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
21
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
24
Goserelin Approved Phase 4 65807-02-5 5311128 47725
25
Desogestrel Approved Phase 4 54024-22-5 40973
26
Dienogest Approved Phase 4 65928-58-7 13175121 68861
27
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
28
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
29
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
30
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
31
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
32
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
33
Beta carotene Approved, Nutraceutical Phase 4 6811-73-0, 7235-40-7 10256668 5280489
34
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
35
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
36
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
37
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
38
Cobalamin Experimental Phase 4 13408-78-1 6857388
39
Fibrinolysin Investigational Phase 4 9004-09-5
40 Aromatase Inhibitors Phase 4
41 Estrogens Phase 4
42 Anesthetics Phase 4
43 Prolactin Release-Inhibiting Factors Phase 4
44 Carotenoids Phase 4
45 Vitamin B3 Phase 4
46 Nicotinic Acids Phase 4
47
Vitamin B2 Phase 4
48 Vitamin B12 Phase 4
49 Vitamin B1 Phase 4
50 Vitamin B 12 Phase 4

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
2 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
5 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
6 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
7 A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03886220 Phase 4 Elagolix;Placebo
8 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Completed NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
9 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
10 Ulipristal Acetate Therapy Versus Uterine Artery Embolization in Management of Uterine Fibroids Completed NCT04832906 Phase 4 Ulipristal Oral Tablet
11 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
12 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
13 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
14 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
15 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
16 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
17 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
18 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Terminated NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
19 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
20 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
21 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
22 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
23 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
24 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
25 Multicenter, Randomized Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids (MRgFUS TUF) Compared to Myomectomy in Symptomatic Medication and Not Sufficiently Treatable Uterine Fibroids Unknown status NCT03948789 Phase 3
26 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Unknown status NCT02942537 Phase 2, Phase 3
27 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
28 An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03751124 Phase 3 Relugolix;Estradiol/norethindrone acetate;Placebo for relugolix;Placebo for E2/NETA
29 A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques Completed NCT00365989 Phase 3
30 Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
31 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02654054 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
32 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids Completed NCT02655224 Phase 3 Relugolix;Relugolix placebo
33 A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03070951 Phase 3 OBE2109;Placebo to match OBE2109;Placebo to match Add-back;Add-back
34 LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03049735 Phase 3 Relugolix;Estradiol/norethindrone acetate;Estradiol/norethindrone acetate placebo;Relugolix placebo
35 LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03103087 Phase 3 Relugolix;Estradiol/norethindrone acetate;Relugolix placebo;Estradiol/norethindrone acetate placebo
36 A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03070899 Phase 3 OBE2109;Placebo to match OBE2109;Placebo to match Add-back;Add-back
37 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02691494 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
38 A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Completed NCT02655237 Phase 3 Relugolix;Relugolix Placebo;Leuprorelin;Leuprorelin Placebo
39 EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids Completed NCT00100191 Phase 3
40 A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
41 LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03412890 Phase 3 Relugolix;Estradiol/norethindrone acetate
42 A Randomized, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids Completed NCT03240523 Phase 3 Vilaprisan (BAY1002670)
43 Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids Completed NCT01141062 Phase 3
44 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
45 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
46 A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids Completed NCT03400943 Phase 3 Vilaprisan (BAY1002670);Placebo
47 Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT02925494 Phase 3 Estradiol/Norethindrone Acetate;Elagolix
48 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Completed NCT02189083 Phase 3 TSD
49 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone
50 A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata Completed NCT00156208 Phase 3 Asoprisnil

Search NIH Clinical Center for Leiomyoma, Uterine

Genetic Tests for Leiomyoma, Uterine

Genetic tests related to Leiomyoma, Uterine:

# Genetic test Affiliating Genes
1 Uterine Leiomyoma 28

Anatomical Context for Leiomyoma, Uterine

Organs/tissues related to Leiomyoma, Uterine:

MalaCards : Uterus, Smooth Muscle, Breast, Liver, Prostate, Bone, Placenta

Publications for Leiomyoma, Uterine

Articles related to Leiomyoma, Uterine:

(show top 50) (show all 6552)
# Title Authors PMID Year
1
A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. 62 57
21460842 2011
2
Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. 53 57
15334541 2004
3
Allelotype of uterine leiomyomas. 62 57
10549262 1999
4
Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. 53 57
9892177 1999
5
Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. 53 57
9253340 1997
6
Involvement of the long arm of chromosome 12 in chromosome rearrangements of uterine leiomyoma. 62 57
3355999 1988
7
Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. 57
23040493 2012
8
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. 57
21868628 2011
9
Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. 57
19132395 2009
10
Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. 62 46
17765232 2008
11
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 62 46
18403645 2008
12
A specific translocation, t(12;14)(q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. 57
3355995 1988
13
Clinical features at the time of non-hysteroscopic myomectomy before pregnancy, which affect adverse pregnancy outcomes: a retrospective cohort study. 41
36463110 2022
14
HYSTEROSCOPIC MYOMECTOMY. 41
36422166 2022
15
Uterine smooth muscle tumor of uncertain malignant potential: A review of current knowledge. 41
36427995 2022
16
The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. 53 62
20056218 2010
17
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 53 62
20414849 2010
18
Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. 53 62
20200259 2010
19
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 53 62
20124487 2010
20
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 53 62
19135657 2010
21
Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids. 53 62
19639498 2010
22
Ascites in puerperium: a rare case of atypical pseudo-Meigs' syndrome complicating the puerperium. 53 62
19322576 2009
23
A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. 53 62
19734847 2009
24
No association between estrogen receptor beta polymorphisms and uterine leiomyoma. 53 62
19715484 2009
25
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 53 62
19700613 2009
26
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 53 62
19808856 2009
27
Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. 53 62
19809499 2009
28
Family history of uterine fibroids associated with low level of fumarate hydratase in leiomyomata cells. 53 62
19595497 2009
29
Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. 53 62
19499404 2009
30
Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. 53 62
19305350 2009
31
Pulmonary benign metastasizing leiomyoma in a postmenopausal woman. 53 62
19506459 2009
32
High aromatase expression in uterine leiomyoma tissues of African-American women. 53 62
19240151 2009
33
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 53 62
19151755 2009
34
Sex hormone binding globulin and aging. 53 62
18956301 2009
35
Sex steroidal modulation of collagen metabolism in uterine leiomyomas. 53 62
19400409 2009
36
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 53 62
18249392 2009
37
Novel progesterone receptor modulators with gene selective and context-dependent partial agonism. 53 62
19013437 2009
38
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity. 53 62
18848966 2008
39
Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. 53 62
19075141 2008
40
Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats. 53 62
18824103 2008
41
Selective progesterone receptor modulators 2: use in reproductive medicine. 53 62
18778185 2008
42
Combined differential gene expression profile and pathway enrichment analyses to elucidate the molecular mechanisms of uterine leiomyoma after gonadotropin-releasing hormone treatment. 53 62
18258233 2008
43
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 53 62
19012097 2008
44
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 53 62
18701604 2008
45
Incidence, aetiology and epidemiology of uterine fibroids. 53 62
18534913 2008
46
The catechol-O-methyltransferase (COMT) gene polymorphism and prevalence of uterine fibroids. 53 62
18752908 2008
47
Association of the CYP17 gene polymorphism with risk for uterine leiomyoma in Brazilian women. 53 62
18645709 2008
48
Labial aggressive angiomyxoma associated with endometrial hyperplasia and uterine leiomyoma: a case report and review of the literature. 53 62
18839858 2008
49
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. 53 62
18231572 2008
50
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 53 62
18281245 2008

Variations for Leiomyoma, Uterine

ClinVar genetic disease variations for Leiomyoma, Uterine:

5 (show all 32)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 DLX3 NM_005220.3(DLX3):c.263A>G (p.Tyr88Cys) SNV Likely Pathogenic
1326290 rs772972332 GRCh37: 17:48072100-48072100
GRCh38: 17:49994736-49994736
2 FH NM_000143.4(FH):c.322C>T (p.Gln108Ter) SNV Likely Pathogenic
393560 rs1060499630 GRCh37: 1:241676959-241676959
GRCh38: 1:241513659-241513659
3 PTCH1 NM_001083603.3(PTCH1):c.109del (p.Cys37fs) DEL Uncertain Significance
523402 rs1554710890 GRCh37: 9:98278994-98278994
GRCh38: 9:95516712-95516712
4 HMGA2 NM_003483.6(HMGA2):c.283-2A>G SNV Uncertain Significance
800987 rs1592471112 GRCh37: 12:66357023-66357023
GRCh38: 12:65963243-65963243
5 MED12 NM_005120.3(MED12):c.111_155del (p.Ala38_Ser52del) DEL Not Provided
92203 rs199469681 GRCh37: X:70339233-70339277
GRCh38: X:71119383-71119427
6 MED12 NM_005120.3(MED12):c.107_111delinsGC (p.Leu36_Thr37delinsArg) INDEL Not Provided
92202 rs199469679 GRCh37: X:70339230-70339234
GRCh38: X:71119380-71119384
7 MED12 NM_005120.3(MED12):c.107T>G (p.Leu36Arg) SNV Not Provided
92201 rs199469667 GRCh37: X:70339230-70339230
GRCh38: X:71119380-71119380
8 MED12 NM_005120.3(MED12):c.103_138del (p.Glu35_Asn46del) DEL Not Provided
92200 rs199469678 GRCh37: X:70339224-70339259
GRCh38: X:71119374-71119409
9 MED12 NM_005120.3(MED12):c.100-8T>A SNV Not Provided
92199 rs199469675 GRCh37: X:70339215-70339215
GRCh38: X:71119365-71119365
10 MED12 NM_005120.3(MED12):c.100_141del (p.Asp34_Asn47del) DEL Not Provided
92198 rs199469677 GRCh37: X:70339223-70339264
GRCh38: X:71119373-71119414
11 MED12 NM_005120.3(MED12):c.100-1_139del DEL Not Provided
92197 rs199469676 GRCh37: X:70339221-70339261
GRCh38: X:71119371-71119411
12 MED12 NM_005120.3(MED12):c.113_121del (p.Ala38_Asn40del) DEL Not Provided
92204 rs199469682 GRCh37: X:70339235-70339243
GRCh38: X:71119385-71119393
13 MED12 NM_005120.3(MED12):c.117_122del (p.Asn40_Val41del) DEL Not Provided
92205 rs199469683 GRCh37: X:70339239-70339244
GRCh38: X:71119389-71119394
14 MED12 NM_005120.3(MED12):c.118_132del (p.Asn40_Gly44del) DEL Not Provided
92206 rs199469684 GRCh37: X:70339241-70339255
GRCh38: X:71119391-71119405
15 MED12 NM_005120.3(MED12):c.118_134delinsTA (p.Asn40_Phe45delinsTyr) INDEL Not Provided
92207 rs199469680 GRCh37: X:70339241-70339257
GRCh38: X:71119391-71119407
16 MED12 NM_005120.3(MED12):c.118_146delinsTT (p.Asn40_Pro49delinsPhe) INDEL Not Provided
92208 rs199469685 GRCh37: X:70339241-70339269
GRCh38: X:71119391-71119419
17 MED12 NM_005120.3(MED12):c.122_148del (p.Val41_Pro49del) DEL Not Provided
92209 rs199469686 GRCh37: X:70339243-70339269
GRCh38: X:71119393-71119419
18 MED12 NM_005120.3(MED12):c.122_163del (p.Val41_Asp54del) DEL Not Provided
92210 rs199469687 GRCh37: X:70339242-70339283
GRCh38: X:71119392-71119433
19 MED12 NM_005120.3(MED12):c.123_152del (p.Lys42_Val51del) DEL Not Provided
92211 rs199469688 GRCh37: X:70339243-70339272
GRCh38: X:71119393-71119422
20 MED12 NM_005120.3(MED12):c.126_131del (p.Lys42_Gly44delinsAsn) DEL Not Provided
92212 rs199469689 GRCh37: X:70339249-70339254
GRCh38: X:71119399-71119404
21 MED12 NM_005120.3(MED12):c.126_140del (p.Lys42_Asn46del) DEL Not Provided
92213 rs199469690 GRCh37: X:70339247-70339261
GRCh38: X:71119397-71119411
22 MED12 NM_005120.3(MED12):c.128A>C (p.Gln43Pro) SNV Not Provided
92214 rs199469668 GRCh37: X:70339251-70339251
GRCh38: X:71119401-71119401
23 MED12 NM_005120.3(MED12):c.129_137del (p.Gln43_Asn46delinsHis) DEL Not Provided
92215 rs199469691 GRCh37: X:70339251-70339259
GRCh38: X:71119401-71119409
24 MED12 NM_005120.3(MED12):c.129_143del (p.Gly44_Gln48del) DEL Not Provided
92216 rs199469692 GRCh37: X:70339250-70339264
GRCh38: X:71119400-71119414
25 MED12 NM_005120.3(MED12):c.130G>A (p.Gly44Ser) SNV Not Provided
92217 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
26 MED12 NM_005120.3(MED12):c.130G>C (p.Gly44Arg) SNV Not Provided
92218 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
27 MED12 NM_005120.3(MED12):c.130G>T (p.Gly44Cys) SNV Not Provided
92219 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
28 MED12 NM_005120.3(MED12):c.131G>A (p.Gly44Asp) SNV Not Provided
92220 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
29 MED12 NM_005120.3(MED12):c.131G>C (p.Gly44Ala) SNV Not Provided
92221 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
30 MED12 NM_005120.3(MED12):c.131G>T (p.Gly44Val) SNV Not Provided
92222 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
31 MED12 NM_005120.3(MED12):c.133_144del (p.Phe45_Gln48del) DEL Not Provided
92223 rs199469693 GRCh37: X:70339256-70339267
GRCh38: X:71119406-71119417
32 MED12 NM_005120.3(MED12):c.149_163del (p.Ala50_Asp54del) DEL Not Provided
92224 rs199469694 GRCh37: X:70339270-70339284
GRCh38: X:71119420-71119434

Copy number variations for Leiomyoma, Uterine from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70739 12 64503703 64646338 Duplication HMGA2 Uterine leiomyoma
2 230938 8 100959547 100975071 Translate COX6C Uterine leiomyoma

Expression for Leiomyoma, Uterine

Search GEO for disease gene expression data for Leiomyoma, Uterine.

Pathways for Leiomyoma, Uterine

Pathways related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.03 MIR34A MIR27A MIR212 MIR21 MIR203A
2 10.93 MIR542 MIR29C MIR27A MIR23B MIR21 MIR203A
3
Show member pathways
10.6 MIRLET7C MIR29C

GO Terms for Leiomyoma, Uterine

Cellular components related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 MIRLET7C MIR335 MIR323A MIR30A MIR29C MIR27A
2 RISC complex GO:0016442 9.9 MIR10A MIR139 MIR144 MIR150 MIR196B MIR197
3 extracellular vesicle GO:1903561 9.5 MIRLET7C MIR34A MIR30A MIR29C MIR27A MIR23B

Biological processes related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.88 MIR10A MIR139 MIR144 MIR150 MIR196B MIR197
2 negative regulation of gene expression GO:0010629 9.87 MIR34A MIR29C MIR27A MIR212 MIR21 MIR144
3 negative regulation of cell migration GO:0030336 9.77 MIR34A MIR335 MIR29C MIR212 MIR21
4 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.58 MIR27A MIR150 MIR10A
5 negative regulation of angiogenesis GO:0016525 9.55 MIR10A MIR21 MIR212 MIR29C MIR34A
6 negative regulation of cell cycle G1/S phase transition GO:1902807 9.49 MIR29C MIR10A
7 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.48 MIR323A MIR144
8 negative regulation of cholesterol efflux GO:0090370 9.46 MIR27A MIR144
9 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.43 MIR27A MIR21
10 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.43 MIR27A MIR21 MIR10A
11 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIR29C MIR27A MIR212 MIR21 MIR144

Molecular functions related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 MIR34A MIR335 MIR323A MIR30A MIR29C MIR27A
2 mRNA base-pairing translational repressor activity GO:1903231 9.5 MIRLET7C MIR34A MIR335 MIR323A MIR32 MIR30A

Sources for Leiomyoma, Uterine

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....